Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone vs Placebo in Idiopathic Pulmonary Fibrosis (Phase 3, Three-Arm, UK)
2006-000252-41Phase 3Completed
- Sponsor
- InterMune
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pirfenidone in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by InterMune. Primary endpoint: Absolute change in percent predicted FVC from baseline to Week 72. Started Apr 2006; status: completed.
02
Drugs
pirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2006-000252-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000252-41.